Summary We recently defined a new early prognostic factor, the ER+(R) status, which permits the discrimination of a group presenting a high risk of early relapse among the ER' patients. This group was referred to as ER+(R2) in contrast to ER+(R1) which corresponded to the group of ER' patients having a lower risk of early relapse. Taking into account the whole population including the ER-and inflammatory tumours, we have extended this view and showed that ER+(R) status is a significant predictor of disease-free survival. Determination of c-erbB-2 mRNA levels in the same series of tumours showed that high expression of c-erbB-2 mRNA is significantly correlated with ER-, inflammatory tumours and with lymph nodes involvement. Moreover, a multivariate analysis showed that c-erbB-2 mRNA overexpression was a significant predictor of early relapse (P=0.02), as significant as ER negativity and ER+(R2). For ER' patients a high level of c-erbB-2 mRNA constitutes a higher risk of relapse for both ER+(RI) and ER+(R2) patients. However, in the case of ER-patients, early relapses were strongly correlated with c-erbB-2 overexpression. The counterpart of this observation is that ER-patients with no overexpression of c-erbB-2 constitute a group with a relatively good prognosis.
Management of breast cancer treatment depends on a good knowledge of the prognostic factors enabling the identification of patients with either a low or high risk of recurrence. A knowledge of the steroid receptor status, specifically the oestrogen receptor (ER), should allow the prediction of the response to hormonal therapy and to some extent disease-free survival, site of relapse and overall survival (Knight et al., 1977; Pichon et al., 1980; Clark et al., 1983; Allegra et al., 1979; Blanco et al., 1984; Fisher et al., 1983; Hahnel et al., 1979; Saez et al., 1983) . Although there is a general agreement on the higher risk of relapse for receptornegative (ER-) patients, the prognostic value of ER status is not accepted by all authors (Aamdal et al., 1984; Howell et al., 1984; Felman et al., 1986; Parl et al., 1984) . Among ER-positive (ER') patients regarded as having a more favourable prognosis, we have recently defined a group presenting a high risk of relapse (May et al., 1989) . This group of patients, called ER+(R2), has been characterised by a ratio of (ER-protein in fmol per mg total proteins) to (ERmRNA in pg per 4pg total RNA) higher than 1.5. According to these results, ER+(R) status has been assigned as an early prognostic factor.
On the other hand, amplification of the c-erbB-2 gene is an alteration frequently associated with breast cancer. This gene encodes a transmembrane protein that shows extensive homology with the receptor for epidermal growth factor (Coussens et al., 1985; Bargmann et al., 1986; Yamamoto et al., 1986) , indicating that c-erbB-2 is a membrane-bound receptor. A ligand for c-erbB-2, however, has not yet been identified. A number of studies regarding amplification of this gene in primary human breast cancer has been published (see Table I for references). Depending on the authors, incidence of amplification varies from 10 to 40%. Amplification of c-erbB-2 receptor gene in human breast cancer was associated with high levels of both mRNA and protein (see Table I for references). However, overexpression of the c-erbB-2 gene depends not only on gene amplification, since elevated levels of the c-erbB-2 receptor and c-erbB-2 specific mRNA were observed in tumours containing a single copy of the oncogene (Lacicix et al., 1989; Berger et al., 1988; Guerin et al., 1989; Venter et al., 1987 The association between amplification of the c-erbB-2 gene and poor prognosis in human breast cancer was first reported by Slamon et al. (1987) . Since then, contradictory results concerning the associations between c-erbB-2 amplification, clinicopathological features and risk of relapse have been reported (see Table 1 ). It is interesting to note that significant associations between c-erbB-2 amplification and positive nodal status as well as the worst histological grade and increase in relapse are observed more often in the groups of patients having a higher incidence of amplification and/or overexpression. In fact, recent results of Slamon et al. (1989 ), Wright et al. (1989 and Tandon et al. (1989) obtained with large populations of patients strongly support the assumption that c-erbB-2 gene amplification and/or overexpression are reliable guides to the prognosis of breast cancer.
The present study was performed in an attempt to correlate the prognostic significance of ER+(R) status with the c-erbB-2 prognostic factor. As direct measurement of c-erbB-2 gene expression may be more relevant to disease (Tandon et al., 1989 ), we have assessed the level of c-erbB-2 specific mRNA in the series of breast cancers previously analysed for the expression of ER-specific mRNA (May et al., 1989) .
Results showed that ER+(R) status and c-erbB-2 mRNA are two significant independent predictors of early relapse.
Materials and methods

Patients
Samples of untreated and non-metastatic breast carcinomas were obtained by biopsy or tumorectomy from 89 patients treated at 'Institut Gustave-Roussy' (Villejuif, France). Seventy-six patients had an operable tumour. Depending on the tumour size, either mastectomy or conservative treatment was performed. In case of axillary nodes invasion, adjuvant treatment was prescribed: taximofen for post-menopausal women, chemotherapy for premenopausal women with locoregional radiotherapy for both groups of patients. The remaining 13 patients had an inflammatory non-metastatic tumour. This diagnosis was made on the basis of clinical symptoms (oedema, hotness, redness in more than one-third of the breast) and confirmed by biopsy. These patients were treated by association of chemo-, radio-and hormonotherapy. No surgery was performed. 
Chemicals
3H-oestradiol (3H-E2) (100 Ci mmol-') was obtained from the CEA (Commissariat i l'Energie Atomique, France). All other reagents were of the highest grade available.
ER assay ER levels were determined by the one-dose saturation method (5 nM) using 3H-E2 as previously described (Martin et al., 1981) . The total amount of receptor was measured after extraction with a buffer containing 0.4 M KCI. Tumours with an ER level higher than 10 fmol mg-' of total protein were considered as positive.
RNA extraction
Total cellular RNA was isolated from 0.3 to 0.5 g of frozen tumour by the guanidium-caesium chloride method (Glisin et al., 1974) . Yields were quantified by spectrophotometry. The quality of RNA was controlled by monitoring the integrity of the 28 S and 18 S ribosomal bands following agarose gel electrophoresis.
Northern blot analysis
Total RNA (4;Lg) was analysed by Northern blot as previously described (May et al., 1989) . Rehybridisation of filters was performed after treating Hybond N membrane (Amersham) for 1 h in Tris-HCI 0.005 M, EDTA 0.002 M, Denhart (pH 8) at 65C. RNA concentrations were determined by quantitative densitometric scanning of appropriately exposed autoradiograms. Quantification was performed by running in parallel known amounts of a single-stranded recombinant DNA containing the insert used as probe. Each sample was analysed at least twice and results were normalised relative to the steady state level of P-actin mRNA.
Two aliquots of RNA extracted from the tumour of patient no. 60 were run on every gel and used as reference for comparison purposes.
The following DNA or plasmid probes were used in this study after 32P-labelling by the 'random primed' DNA labelling method (Boehringer Kit, Mannheim); the 1200-bp Accl/ BamHI fragment of pMAC1 17 (ATCC collection) specific to the c-erbB-2 mRNA and chicken-specific f-actin (May et al., 1989) .
Statistical methods Survival times were measured from the date of diagnosis and the multiple regression model developed by Cox (1972) for censored survival data was used. This both allows the consideration of several variables simultaneously and the identification of the variables which have an important effect on disease recurrence and survival. Disease-free survival (DFS) curves were obtained by the product limit method of Kaplan and Meier (1958) . Comparisons of DFS curves were based on the log rank test and all other comparisons were made using the x2 test. We have previously quantified the ER-binding activities and the steady-state levels of ER-mRNA for untreated, primary breast carcinomas (May et al., 1989 ). In the current study, we performed a quantitative analysis of steady-state levels of c-erbB-2 mRNA on the same RNA preparations except for one additional ER-carcinoma. Northern blot analysis of total RNA from 13 different primary breast tumours. 4 pg of total RNA were electrophoresed and hybridised with a c-erbB-2 cDNA probe. After autoradiography (4 days without an intensifying screen), blots were dehybridised and then hybridised with a P-actin-specific probe. The two resulting autoradiograms are superimposed. Numbering of the patients is identical to that in the previous paper (May et al., 1989 (Kraus et al., 1987) . Fiftyseven per cent of the population correspond in fact to this c-erbB-2 mRNA level ( Figure 2 ). The remaining patients were divided into four equal groups corresponding to 5-10, 10-20, 20-50 and 50 -190 pg of specific mRNA per 4pg of total RNA, respectively (Figure 2 ). These groups were analysed to establish the cut-off value of c-erbB-2 mRNA that would best distinguish patients at high risk of relapse. A cut-off value of 20 turned out to provide a significant separation. Our population of 89 patients was then separated into three categories corresponding to normal (less than 5 pg), moderate (5-20 pg) and high (20-190 pg) level expression. High levels of c-erbB-2 mRNA were detected in 23% (20/89) of tumours (Table II) Correlations between clinico-pathological data and the level of c-erbB-2 mRNA expression are presented in Table II . We have included the ER+(R) status according to previously published results (May et al., 1989) . This parameter, estimated for ER' tumours, was defined by the ratio ER-protein (expressed in fmol mg-') to ER-mRNA (expressed in pg per 4 pg of total RNA). Groups ER+(RI) and ER+(R2) correspond to tumours having a ratio lower and higher than 1.5, respectively.
Results presented in Table II showed that high levels of c-erbB-2 mRNA were significantly correlated with (i) inflammatory carcinoma (P = 0.007), (ii) presence of involved lymph nodes (P = 0.03) and (iii) ER negativity (P = 0.02). There was no significant correlation between c-erbB-2 mRNA levels and age of the patient at diagnosis, histological grade or ER+(R) status. (Contesso et al., 1975) .
In agreement with previously published data (Lacroix et al., 1989; Guerin et al., 1989) , univariate survival analysis showed that patients with inflammatory carcinoma had a very poor prognosis (P< 10-4 c-erbB-2 mRNA overexpression was as significant as inflammatory tumours on univariate analysis. Moreover, high levels of c-erbB-2 mRNA (>20 pg per 4 iLg of total RNA) was still highly significant on multivariate analysis in predicting relapse in the relative short-term (P <0.02). The group of patients with normal levels of c-erbB-2 mRNA ( < 5 pg) was taken as reference in this analysis. It is interesting to note that patients with moderate overexpression (5-20 pg) had the same low-risk of relapse as patients with normal levels of c-erbB-2 mRNA.
On the other hand, both ER-and ER+(R) status were highly significant in predicting disease outcome on univariate as well as on multivariate analysis. These analyses (Table III) were performed by grouping the 89 tumours into three groups corresponding to ER-, ER+(RI) and ER+(R2) tumours, the ER+(RI) group being reference for multivariate analysis. Both ER-and ER+(R2) patients had a high risk of early relapse (P=0.01). The risk of relapse for ER+(R2) patients is comparable to that of patients which have an overexpressed c-erbB-2 gene. Our first identification of ER+(R2) as a predictor of early relapse was performed on a population confined to ER' patients having a non-inflammatory tumour. Results presented here, extend our previous conclusion to the whole population, including ER-and inflammatory tumours. Figure 3 shows the disease-free interval for ER' patients. The ER+(R2) group was at a higher risk of relapse than the ER+(R1) group for patients having normal or moderate level of c-erbB-2 mRNA as well as for those overexpressing c-erbB-2 mRNA. Moreover, high level of c-erbB-2 mRNA constituted an additional risk of relapse for both ER+(R1) and ER+(R2) patients.
The relationship between expression of c-erbB-2 mRNA and disease-free survival of 21 ER-patients is given in Figure 4 . Eight out of nine observed relapses were associated with c-erbB-2 mRNA overexpression. This indicated that, for ER-patients, relapses were strongly correlated with c-erbB-2 gene overexpression. It is interesting to note that ERpatients expressing normal or moderate levels of c-erbB-2 mRNA constitute a group having a relative low risk of relapse, comparable to the low risk of relapse of ER+(RI) patients. In other words, ER+(R2) is a better predictor of relapse than ER negativity for patients expressing relatively low levels of c-erbB-2 mRNA (<20 pg). Figure 4 Disease-free survival curves in ER-negative breast cancer patients stratified by c-erbB-2 mRNA levels. c-erbB-2 mRNA was expressed in pg per 4 ig of total RNA extracted from tumours. Two events were noted at 3 months in the group of patients overexpressing c-erbB-2 mRNA.
Discussion
We recently defined a new early prognostic factor, the ER+(R) status, which permits one to discriminate among the ER positive patients, a group presenting a high risk of early relapse (May et al., 1989) . This group was referred to as ER+(R2) in contrast to ER+(R1) which corresponded to a group of ER positive patients having a lower risk of early relapse.
In the present study we performed a multivariate analysis to evaluate the prognostic significance of ER+(R) status in relation to c-erbB-2 mRNA overexpression and other classical parameters used in breast cancer prognosis.
Levels of c-erbB-2 mRNA were evaluated by Northern blotting in 89 primary human breast carcinomas from nontreated patients for whom comprehensive clinical follow-up data was available. High expression of c-erbB-2 mRNA is significantly correlated with ER negativity, inflammatory tumours and with lymph node involvement, all of which are indicators of poor prognosis. While conflicting results concerning the correlation between c-erbB-2 gene amplification and/or overexpression and other classical prognostic factors have been reported in the literature (see Table I ), our results are in agreement with those obtained by Guerin et al. (1989) from an independent population of patients from the same Cancer Institute.
Concerning the prognostic value of ER+(R) status, we found no correlation between this factor and c-erbB-2 mRNA. We previously showed the absence of a significant correlation between ER+(R) status and histological grade of the tumour or lymph node involvement. Results presented here extend the assessment of ER+(R) status as an independent prognostic factor to c-erbB-2 gene expression.
In a multivariate survival analysis, with a median followup of 30 months, we found that c-erbB-2 mRNA overexpression was a highly significant short-term predictor of relapse (P = 0.02). These results agree with those published by Varley et al. (1987 ), Slamon et al. (1987 , 1989 , Wright et al. (1989) and Tandon et al. (1989) , although the medium follow-up available for our studies was shorter than that for these authors.
It is interesting to note that the level of c-erbB-2 transcripts significant for the prediction of short-term relapse corresponds to at least 10-fold the MCF-7 level considered as normal. This observation corroborates published data showing that gene amplification correlated with the highest levels of overexpression and that the group with the highest copy number showed the greatest difference in prognosis when compared with the single copy group (Slamon et al., 1987 (Slamon et al., , 1989 . Therefore, analysis of c-erbB-2 mRNA expression may be a sensitive assay provided that the cut-off value is carefully determined.
We found no correlation between lymph node involvement and early relapse. This observation is not inconsistent with previous data giving a significant value of lymph node involvement with longer available follow-up (Contesso et al., 1975) . Considering this observation with the fact that c-erbB-2 overexpression was significantly correlated with lymph node involvement and disease free survival, it is tempting to suggest that c-erbB-2 overexpression is an earlier event than lymph node involvement towards the development or progression of breast cancer. This assumption is in agreement with the fact that an overexpression of c-erbB-2 may be detected as early as stage I and II of mammary tumours (Lacroix et al., 1989) .
On the other hand, multivariate analysis showed that the two other worst factors for predicting a poor short-term prognosis were ER negativity and ER+(R2). Previously, we evaluated the prognostic significance of ER+(R) status from a population restricted to ER' patients. Here we extended this idea and showed that ER+(R) status is a significant predictor of disease-free survival for the whole population including the ER-patients and inflammatory tumours. In a multivariate analysis including clinical tumour type, c-erbB-2 expression and ER-/ER+(R) status, inflammatory tumours are not longer significant whereas ER-and ER+(R2) are.
The results of the log rank test (Table IV) and the DFS curves (Figures 2 and 3) showed that patients having a particularly poor prognosis were those with tumours containing high-levels of c-erbB-2 mRNA and either ER-or ER' (R2). An unexpected observation was that ER-patients with no overexpression of c-erbB-2 had a relatively low risk of early relapse.
In conclusion, data presented here and elsewhere (May et al., 1989 ) strongly suggest that both populations of ER' and ER-patients could be divided into two groups presenting either a low or high risk of early relapse. We found that among ER' patients, ER+(R2) patients had a higher risk of early relapse especially when c-erbB-2 was overexpressed. On the contrary, we observed that ER-patients with low or moderate amounts of c-erbB-2 had a good short-term prognosis.
